Global Cord Blood Corporation (NYSE:CO)

Wednesday, November 20, 2019 | Web News
HONG KONG, Nov. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's...
Wednesday, October 16, 2019 | Web News
NEW YORK, Oct. 16, 2019 /PRNewswire/ -- The Committee for China Cord Fairness (the "Committee") today announced that both...
Wednesday, August 28, 2019 | Web News
First Quarter 2020 Financial Results Revenues increased by 16.9% year-over-year ("YoY") to RMB273.4 million ($39.8...
See All Research...
Tuesday, April 27, 2021, 9:30 AM
Ark Restaurants (ARKR) – No Cookie Cutter Here, But The Underlying Value Seems Very Substantial
See All Articles and Reports...

China Cord Blood Corporation (formerly Pantheon China Acquisition Corp., is a special purpose acquisition company formed for the purpose of acquiring, through a stock exchange, asset acquisition or other similar business combination) is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

Last updated July 30, 2008


Market Data powered by QuoteMedia. Terms of Use